Treatment of painful menstruation - ayurveda
Phase 2
- Conditions
- Health Condition 1: null- Patients suffering from dysmenorrhoea(Kashtartava) more than 3 cycles
- Registration Number
- CTRI/2017/04/008296
- Lead Sponsor
- Parul Institute Of Ayurveda
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
1)Patients coming with chief complaint of painful menses
2)Age between 16 to 25 yrs
3)Patients suffering from dysmenorrhoea more than 3 cycles.
Exclusion Criteria
1)Patients below 15yrs and above 25yrs
2)Patients having congenital anomalies leading to dysmenorrhoea
3)Patients on hormonal therapy and Oral Contraceptive pills
4)Patients having Any uterine pathology like fibroid, adenomyosis, endometriosis.
5)Patients is suffering from Acute infections, menorrhagia
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Pain reduction in Kashtartava by by using VMS- Verbal multidimensional scoring system. <br/ ><br>2.Changes in Haematological parameters. <br/ ><br>3.Improvement in associated symptoms like Alpaartava, Prasek, Chhardi, Vibhandha, Shrama, Aruchi, Vankshana Shoola, Kati-Janu Shoola. <br/ ><br>4.For subjective parameters especially on Ayurvedic parlance suitable scoring pattern shall be developed.Timepoint: all outcome will be observed every month. and final outcome will be observed after 2 months of administration of medicines
- Secondary Outcome Measures
Name Time Method The total effect of the therapy will be assessed considering to the overall improvement in signs and symptoms. For this purpose, following categories will be maintained. <br/ ><br>1.Complete remission: 76%-100% relief in the signs and symptoms will be considered as complete resmission. <br/ ><br>2.Marked improvement: 51%-75% relief in the signs and symptoms. <br/ ><br>3.Improved: 26%-50% relief <br/ ><br>4.Unchanged:Below 25% relief.Timepoint: Follow up after 1 month during treatment and after completion of treatment for 2 cycles.